NCT04464226 2026-04-15Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerBayerPhase 3 Active not recruiting402 enrolled
NCT06169124 2026-04-13Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting37 enrolled
NCT05050084 2026-04-08Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNRG OncologyPhase 3 Active not recruiting2,050 enrolled
NCT06734130 2026-04-01Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Active not recruiting25 enrolled
NCT04484818 2026-03-23Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE StudyEastern Cooperative Oncology GroupPhase 3 Active not recruiting27 enrolled